DENALI THERAPEUTICS INC (DNLI) Stock Price, Quote, News and Overview
NASDAQ:DNLI - Nasdaq - US24823R1059 - Common Stock - Currency: USD
DNLI Quote, Performance and Key Statistics
13.89
-0.2 (-1.42%)
The current stock price of DNLI is 13.89 USD. In the past month the price increased by 1.46%. In the past year, price decreased by -38.62%.
DNLI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.31B | ||
| AMGN | AMGEN INC | 13.94 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
| ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.33 | 26.73B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
| NTRA | NATERA INC | N/A | 23.47B | ||
| INSM | INSMED INC | N/A | 18.70B | ||
| BIIB | BIOGEN INC | 8.03 | 18.62B |
Related stock screener links
About DNLI
Company Profile
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 422 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Company Info
DENALI THERAPEUTICS INC
161 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Ryan J. Watts
Employees: 422
Phone: 16508668547
DENALI THERAPEUTICS INC / DNLI FAQ
What is the stock price of DENALI THERAPEUTICS INC today?
The current stock price of DNLI is 13.89 USD. The price decreased by -1.42% in the last trading session.
What is the ticker symbol for DENALI THERAPEUTICS INC stock?
The exchange symbol of DENALI THERAPEUTICS INC is DNLI and it is listed on the Nasdaq exchange.
On which exchange is DNLI stock listed?
DNLI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DENALI THERAPEUTICS INC stock?
25 analysts have analysed DNLI and the average price target is 33.59 USD. This implies a price increase of 141.81% is expected in the next year compared to the current price of 13.89. Check the DENALI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DENALI THERAPEUTICS INC worth?
DENALI THERAPEUTICS INC (DNLI) has a market capitalization of 2.02B USD. This makes DNLI a Mid Cap stock.
How many employees does DENALI THERAPEUTICS INC have?
DENALI THERAPEUTICS INC (DNLI) currently has 422 employees.
What are the support and resistance levels for DENALI THERAPEUTICS INC (DNLI) stock?
DENALI THERAPEUTICS INC (DNLI) has a support level at 13.79 and a resistance level at 14.13. Check the full technical report for a detailed analysis of DNLI support and resistance levels.
Is DENALI THERAPEUTICS INC (DNLI) expected to grow?
The Revenue of DENALI THERAPEUTICS INC (DNLI) is expected to grow by 160.84% in the next year. Check the estimates tab for more information on the DNLI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DENALI THERAPEUTICS INC (DNLI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DNLI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DNLI, evaluating the profitability, health, valuation and growth aspects
- DENALI THERAPEUTICS INC (DNLI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DENALI THERAPEUTICS INC (DNLI) Sales and EPS estimates to see what analysts future expectations are.
- DENALI THERAPEUTICS INC (DNLI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DENALI THERAPEUTICS INC (DNLI) Insider and Institutional Ownership to learn about the owners and their transactions.
- DENALI THERAPEUTICS INC (DNLI) Stock Chart to make your own analysis
- DENALI THERAPEUTICS INC (DNLI) Latest news and press-releases to stay up to date.
Does DENALI THERAPEUTICS INC (DNLI) stock pay dividends?
DNLI does not pay a dividend.
When does DENALI THERAPEUTICS INC (DNLI) report earnings?
DENALI THERAPEUTICS INC (DNLI) will report earnings on 2025-07-30.
What is the Price/Earnings (PE) ratio of DENALI THERAPEUTICS INC (DNLI)?
DENALI THERAPEUTICS INC (DNLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.67).
What is the Short Interest ratio of DENALI THERAPEUTICS INC (DNLI) stock?
The outstanding short interest for DENALI THERAPEUTICS INC (DNLI) is 9.34% of its float. Check the ownership tab for more information on the DNLI short interest.
DNLI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DNLI. When comparing the yearly performance of all stocks, DNLI is a bad performer in the overall market: 85.94% of all stocks are doing better.
DNLI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DNLI. The financial health of DNLI is average, but there are quite some concerns on its profitability.
DNLI Financial Highlights
Over the last trailing twelve months DNLI reported a non-GAAP Earnings per Share(EPS) of -2.67. The EPS decreased by -151.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.77% | ||
| ROE | -34.38% | ||
| Debt/Equity | 0 |
DNLI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to DNLI. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of -14.2% and a revenue growth 160.84% for DNLI